pharmaphorum
SEPTEMBER 28, 2021
Prospects for Valneva’s COVID-19 vaccine are up in the air, but another candidate partnered with Pfizer looks increasingly like it could fill the void of an effective shot for Lyme disease. billion contract to supply up to 100 million doses of its COVID-19 vaccine VLA2001.
Pharmaceutical Technology
AUGUST 17, 2022
On August 8, Pfizer and Valneva announced the initiation of a Phase III study with their Lyme disease vaccine , bringing the prospect of an injection to prevent the condition disease one step closer to reality. This means that the vaccine works against multiple serotypes of the disease, she explains. A one-size-fits-all approach.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
DECEMBER 1, 2022
According to GlobalData’s recent report , a total of five marketed messenger RNA (mRNA) non-vaccine products by 2028 will generate over $2 billion, generated by the approval of pipeline agents. The post mRNA non-vaccine therapeutics to generate $2 billion by 2028 appeared first on European Pharmaceutical Review.
European Pharmaceutical Review
FEBRUARY 14, 2023
Recently there have been several key advances in the clinical development of messenger RNA (mRNA) vaccines, including vaccines for RSV and a personalised cancer vaccine. Progress on mRNA vaccines for RSV Moderna’s mRNA vaccine mRNA-1345 demonstrated vaccine efficacy of 83.7
Express Pharma
AUGUST 31, 2023
If successful, this trial will mark the first time an mRNA cancer vaccine and an immune checkpoint inhibitor have shown improved recurrence-free survival rates. OTX-2002 from Omega Therapeutics is an mRNA therapy anticipated to generate $658 million in global sales, representing 33.2 per cent of the total mRNA therapy market by 2029.
epicur
MARCH 10, 2025
Back when I started with Stokes, around 2002, when you talked to a human medicine doctor about compounding, they didn’t really know what compounding was. ” to “Can we give them a vaccine while they’re being treated?” A medication that may be good for a human may not be good for a cat or a dog.
Express Pharma
FEBRUARY 14, 2024
This is because MSF relies on quality-assured vaccines and medicines made in India to treat the people under their care, with its spending on generic medicines procured from India estimated at 95 per cent for HIV, 90 per cent for hepatitis C antivirals, 36 per cent on TB treatments, and 30 per cent on vaccines.
Expert insights. Personalized for you.
105 
Let's personalize your content